Core Insights - Natera, Inc. is a leading company in the medical research industry, focusing on genetic testing and diagnostics, particularly in non-invasive prenatal testing and oncology diagnostics [1] - Cowen & Co. upgraded Natera's stock to a "Buy" rating, indicating a positive outlook for the company, with the stock price at approximately $230.75 [2] - Baird Financial Group Inc. significantly increased its investment in Natera by 277.8%, now holding 26,624 shares valued at around $4.5 million, reflecting strong institutional interest [2] - Other institutional investors, such as Northwestern Mutual Wealth Management Co. and Hilltop National Bank, have also increased their stakes in Natera, suggesting growing confidence in the company's potential [3] Stock Performance - Natera's current stock price is $229.97, showing a decrease of 1.36% or $3.16 [3] - The stock has traded between $229.32 and $234.58 on the day, with a one-year high of $246.90 and a low of $125.38 [3] - Natera has a market capitalization of approximately $31.74 billion and a trading volume of 237,608 shares, maintaining its significance in the market [3]